Pancreatic Cancer and Venous Thromboembolism.
Teagan ProuseMohammad A MohammadSonali GhoshNarender KumarMa Lorena DuhaylungsodRinku MajumderSamarpan MajumderPublished in: International journal of molecular sciences (2024)
Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of all pancreatic cancers and is the most fatal of all cancers. The treatment response from combination chemotherapies is far from satisfactory and surgery remains the mainstay of curative strategies. These challenges warrant identifying effective treatments for combating this deadly cancer. PDAC tumor progression is associated with the robust activation of the coagulation system. Notably, cancer-associated thrombosis (CAT) is a significant risk factor in PDAC. CAT is a concept whereby cancer cells promote thromboembolism, primarily venous thromboembolism (VTE). Of all cancer types, PDAC is associated with the highest risk of developing VTE. Hypoxia in a PDAC tumor microenvironment also elevates thrombotic risk. Direct oral anticoagulants (DOACs) or low-molecular-weight heparin (LMWH) are used only as thromboprophylaxis in PDAC. However, a precision medicine approach is recommended to determine the precise dose and duration of thromboprophylaxis in clinical setting.
Keyphrases
- venous thromboembolism
- direct oral anticoagulants
- papillary thyroid
- squamous cell
- childhood cancer
- risk factors
- minimally invasive
- poor prognosis
- pulmonary embolism
- squamous cell carcinoma
- coronary artery bypass
- coronary artery disease
- young adults
- acute coronary syndrome
- long non coding rna
- lymph node metastasis
- prognostic factors
- percutaneous coronary intervention
- surgical site infection